| Factor | Score | Distribution | Value | Avg | Rank |
|---|---|---|---|---|---|
Valuation | 59 | 20.7x | 17.8x | Around median | |
Growth | 34 | 1.8% | 7.1% | Bottom tier | |
Quality | 78 | 10.7% | 4.5% | Top tier | |
Safety | 58 | 2.4x | 2.6x | Around median | |
Capital Return | 79 | 4.64% | 2.12% | Top tier | |
Momentum | 56 | 3.3% | 2.9% | Around median | |
Sentiment | 45 | 9 | 3 | Around median |
Estimates — analyst targets and a simplified DCF, not investment advice.
Ten ratios that matter, each compared against its sector median and average — so you can see whether a number is rich or cheap relative to peers in the same sector.
Kenvue is a consumer health company that generates revenue through three main segments: Self Care, Skin Health and Beauty, and Essential Health. Its portfolio includes specific brands such as Tylenol, ZYRTEC, Nicorette, Neutrogena, OGX, Listerine, BAND-AID, and Johnson's Baby, and its growth depends on the distribution of these products, innovation, pricing, increased household penetration, and sales through stores and e-commerce. In the Q2 FY2025 earnings call, the company explained that 41 brands out of 115 accounted for more than three-quarters of sales, while the top ten brands in each region generated more than two-thirds of sales.
In the latest available EDGAR data, Kenvue recorded Q1 FY2026 revenue of $3.9 billion, gross profit of $2.3 billion, net income of $474 million, and earnings per share of $0.25; equivalent to a gross margin of approximately 59% and a net income margin of approximately 12%. The twelve-month figures ending in FY2026 were revenue of $15.3 billion, gross profit of $8.9 billion, and net income of $1.6 billion, compared with revenue of $15.1 billion and net income of $1.5 billion in FY2025.
Q2 FY2026 results announced on August 6, 2026 showed revenue of $3.96 billion, slightly below expectations of $3.97 billion, with news reports stating that sales and earnings growth was supported by higher prices and volumes, but without detailed profit or margin figures for that quarter. The latest available full segment breakdown, for Q2 FY2025, showed organic sales declines of 5.9% in Self Care, 3.7% in Skin Health and Beauty, and 2.4% in Essential Health, despite global consumption growth that outpaced organic sales across all three segments.
The analyst consensus on KVUE is neutral, with an average price target of $19.5 and a narrow range of $19 to $20; the average target is below the 52-week range high of $20.82 and above its low of $14.02. A price-to-earnings ratio is not available in the provided data, while the link between the value of the Kimberly-Clark transaction and the performance of its shares adds an independent source of valuation volatility, so current targets reflect a balance between improving EDGAR figures and margin and execution pressures.
Figures in the text are as of 2026-08-28; the live price is shown at the top of the page.
Kenvue generates revenue from three segments: Self Care, Skin Health and Beauty, and Essential Health. The brands mentioned in the company's disclosures include Tylenol, ZYRTEC, Nicorette, Neutrogena, OGX, Listerine, BAND-AID, and Johnson's Baby. In Q2 FY2025, the company said that 41 brands out of 115 generated more than three-quarters of sales. The top ten brands in each region also generated more than two-thirds of sales, making the performance of the leading brands pivotal to results.
Kenvue recorded Q1 FY2026 revenue of $3.9 billion and gross profit of $2.3 billion. Net income was $474 million and earnings per share were $0.25, equivalent to a net margin of approximately 12%. In Q2 FY2026, reported revenue reached $3.96 billion compared with expectations of $3.97 billion, but the context does not provide a detailed net income or margin figure for that quarter.
According to an August 18, 2026 report, the offer to Kenvue shareholders includes $3.50 in cash in addition to a portion of Kimberly-Clark shares. This structure makes the value of the consideration directly linked to the performance of Kimberly-Clark shares, rather than being an entirely fixed cash amount. Approximately 88% of KVUE's 2.14% decline that day was attributed to transaction valuation adjustments, not to a fundamental change in Kenvue's operations. Therefore, the trajectory of Kimberly-Clark shares has become an important factor in valuing the consideration that Kenvue shareholders may receive.
Automated analysis for informational purposes only — not investment advice.
Adult Tylenol in the United States achieved twelve consecutive quarters of share improvement through Q2 FY2025. Nicorette recorded seven consecutive quarters of share gains, supported by increased distribution of lozenges and gum, while ZYRTEC increased its share and household penetration despite a weak allergy season. In Skin Health and Beauty, Neutrogena Face and OGX returned to U.S. consumption growth, and OGX bond protein repair was the company's best innovation since the beginning of FY2025.
In Q2 FY2025, adjusted gross margin contracted by 70 basis points to 60.9%, despite supply chain productivity. The company attributed the pressure to input inflation, unfavorable mix, currency effects, and pricing investments, while net interest expense increased by approximately $2 million to $94 million. The company estimated the total annualized impact of tariffs then in effect at approximately $150 million and said that productivity initiatives would not fully offset margin pressures. In reports dated August 6, 2026, inflation, tariffs, and currency costs continued to be cited as factors pressuring profitability.
Essity announced on August 19, 2026 its intention to acquire Kenvue's feminine care business in Brazil for $284 million. The transaction represents a divestiture of a specific business within Kenvue's portfolio, and the provided data does not include a detailed financial impact on earnings or a completion date. This move is consistent with the broader review of the brand portfolio and strategic alternatives that Kenvue discussed in its Q2 FY2025 earnings call. The available information does not make it possible to determine how the sale proceeds will be used or how much the divested business contributed to revenue.
